A review on Alzheimer's disease pathophysiology and its management: an update

Alzheimer's Association, 2014, Alzheimer's disease facts and figures, Alzheimers Dement, 10, 47, 10.1016/j.jalz.2014.02.001

Ramirez-Bermudez, 2012, Alzheimer's disease: critical notes on the history of a medical concept, Arch Med Res, 43, 595, 10.1016/j.arcmed.2012.11.008

Auld, 2002, Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies, Prog Neurobiol, 68, 209, 10.1016/S0301-0082(02)00079-5

Farlow, 2008, Treatment options in Alzheimer's disease: maximizing benefit, managing expectations, Dement Geriatr Cogn Disord, 25, 408, 10.1159/000122962

Kumar, 2008, Neuropathology and therapeutic management of Alzheimer's disease – an update, Drugs Future, 33, 433, 10.1358/dof.2008.033.05.1192677

Hardy, 2009, The amyloid hypothesis for Alzheimer's disease: a critical reappraisal, J Neurochem, 110, 1129, 10.1111/j.1471-4159.2009.06181.x

Salomone, 2012, New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs, Br J Clin Pharmacol, 73, 504, 10.1111/j.1365-2125.2011.04134.x

Rosenmann, 2013, Immunotherapy for targeting tau pathology in Alzheimers disease and tauopathies, Curr Alzheimer Res, 10, 217, 10.2174/1567205011310030001

Antanitus, 1998, A theory of cortical neuron–astrocyte interaction, Neuroscientist, 4, 154, 10.1177/107385849800400310

Roth, 2005, Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation, Biol Res, 38, 381, 10.4067/S0716-97602005000400011

Subasinghe, 2003, Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes, J Neurochem, 84, 471, 10.1046/j.1471-4159.2003.01552.x

Xu, 2012, Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease, Prog Neurobiol, 97, 1, 10.1016/j.pneurobio.2012.02.002

Armato, 2013, Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia, Int J Mol Med, 31, 3, 10.3892/ijmm.2012.1162

Yasojima, 2001, Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain, Brain Res, 919, 115, 10.1016/S0006-8993(01)03008-6

Eisele, 2010, Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis, Science, 330, 980, 10.1126/science.1194516

Talantova, 2013, Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss, Proc Natl Acad Sci U S A, 110, 2518, 10.1073/pnas.1306832110

Silvestrelli, 2006, Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology, Mech Ageing Dev, 127, 148, 10.1016/j.mad.2005.09.018

Schenk, 1999, Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, 400, 173, 10.1038/22124

Zlokovic, 2004, Clearing amyloid through the blood–brain barrier, J Neurochem, 89, 807, 10.1111/j.1471-4159.2004.02385.x

Sagare, 2007, Clearance of amyloid-β by circulating lipoprotein receptors, Nat Med, 13, 1029, 10.1038/nm1635

Yan, 2009, RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation?, J Alzheimers Dis, 16, 833, 10.3233/JAD-2009-1030

Ghosh, 2012, Developing β-secretase inhibitors for treatment of Alzheimer's disease, J Neurochem, 120, 71, 10.1111/j.1471-4159.2011.07476.x

Chang, 2011, β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice, FASEB J, 25, 775, 10.1096/fj.10-167213

Aisen, 2011, Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Al phase Study), Arch Med Sci, 7, 102, 10.5114/aoms.2011.20612

DaSilva, 2009, Scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease, Alzheimers Dement, 5, 425, 10.1016/j.jalz.2009.04.950

Janusz, 2010, Colostral proline-rich polypeptides – immunoregulatory properties and prospects of therapeutic use in Alzheimers disease, Curr Alzheimer Res, 7, 323, 10.2174/156720510791162377

Jacobsen, 2008, Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade, Proc Natl Acad Sci U S A, 105, 8754, 10.1073/pnas.0710823105

Saito, 2005, Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation, Nat Med, 11, 434, 10.1038/nm1206

Scarpini, 2011, Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial, J Alzheimers Dis, 26, 211, 10.3233/JAD-2011-110134

Hock, 2006, Clinical observations with AN-1792 using TAPIR analyses, Neurodegener Dis, 2, 273, 10.1159/000090368

Nicoll, 2003, Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report, Nat Med, 9, 448, 10.1038/nm840

Buée, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Rev, 33, 95, 10.1016/S0165-0173(00)00019-9

Engel, 2006, Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert, J Neurochem, 99, 1445, 10.1111/j.1471-4159.2006.04139.x

Zhang, 2005, Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proc Natl Acad Sci U S A, 102, 227, 10.1073/pnas.0406361102

Brunden, 2010, Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy, J Neurosci, 30, 13861, 10.1523/JNEUROSCI.3059-10.2010

Gozes, 2011, NAP (davunetide) provides functional and structural neuroprotection, Curr Pharm Des, 17, 1040, 10.2174/138161211795589373

Atamna, 2008, Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways, FASEB J, 22, 703, 10.1096/fj.07-9610com

Rojo, 2010, Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease, J Alzheimers Dis, 19, 573, 10.3233/JAD-2010-1262

Congdon, 2012, Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo, Autophagy, 8, 609, 10.4161/auto.19048

Pfaffendorf, 1997, The interaction between methylene blue and the cholinergic system, Br J Pharmacol, 122, 95, 10.1038/sj.bjp.0701355

Ma, 2013, Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice, J Biol Chem, 288, 4056, 10.1074/jbc.M112.393751

Chai, 2011, Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression, J Biol Chem, 286, 34457, 10.1074/jbc.M111.229633

Puzzo, 2009, Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model, J Neurosci, 29, 8075, 10.1523/JNEUROSCI.0864-09.2009

Park, 2011, Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation, Biochem Biophys Res Commun, 408, 602, 10.1016/j.bbrc.2011.04.068

Froestl, 2013, Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes, J Alzheimers Dis, 33, 547, 10.3233/JAD-2012-121537

Oliveira, 2010, Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits, J Neurosci, 30, 16419, 10.1523/JNEUROSCI.3317-10.2010

Watkins, 1994, Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, JAMA, 271, 992, 10.1001/jama.1994.03510370044030

Zhang, 2008, Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase, Cell Mol Neurobiol, 28, 173, 10.1007/s10571-007-9163-z

Fisher, 2012, Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease, J Neurochem, 120, 22, 10.1111/j.1471-4159.2011.07507.x

Collina, 2013, Sigma receptor modulators: a patent review, Expert Opin Ther Pat, 23, 597, 10.1517/13543776.2013.769522

Echeverria, 2012, Cotinine: a potential new therapeutic agent against Alzheimer's disease, CNS Neurosci Ther, 18, 517, 10.1111/j.1755-5949.2012.00317.x

Rissman, 2007, GABAA receptors in aging and Alzheimer's disease, J Neurochem, 103, 1285, 10.1111/j.1471-4159.2007.04832.x

Limon, 2011, GABAergic drugs and Alzheimer's disease, Future Med Chem, 3, 149, 10.4155/fmc.10.291

Marcade, 2008, Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing, J Neurochem, 106, 392, 10.1111/j.1471-4159.2008.05396.x

Butterfield, 2003, The glutamatergic system and Alzheimer's disease, CNS Drugs, 17, 641, 10.2165/00023210-200317090-00004

Miguel-Hidalgo, 2012, Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β 1–40, Eur J Pharmacol, 692, 38, 10.1016/j.ejphar.2012.07.032

Hellweg, 2012, Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD, Int J Geriatr Psychiatry, 27, 651, 10.1002/gps.2766

Ni, 2013, Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain, J Alzheimers Dis, 33, 841, 10.3233/JAD-2012-121447

Rodriguez, 2012, The serotonergic system in ageing and Alzheimer's disease, Prog Neurobiol, 99, 15, 10.1016/j.pneurobio.2012.06.010

Patat, 2009, Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects, Br J Clin Pharmacol, 67, 299, 10.1111/j.1365-2125.2008.03348.x

Maher-Edwards, 2011, SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study, Int J Geriatr Psychiatry, 26, 536, 10.1002/gps.2562

Gravius, 2011, Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity, Behav Pharmacol, 22, 122, 10.1097/FBP.0b013e328343d804

Motawaj, 2011, Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease, J Pharmacol Exp Ther, 336, 479, 10.1124/jpet.110.174458

Chazot, 2010, Therapeutic potential of histamine H3 receptor antagonists in dementias, Drug News Perspect, 23, 99, 10.1358/dnp.2010.23.2.1475899

Brioni, 2011, Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease, J Pharmacol Exp Ther, 336, 38, 10.1124/jpet.110.166876

Othman, 2013, Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers, Br J Clin Pharmacol, 75, 1299, 10.1111/j.1365-2125.2012.04472.x

Nathan, 2013, The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimers disease: a preliminary investigation, Curr Alzheimer Res, 10, 240, 10.2174/1567205011310030003

Cottrell, 2002, The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease, Neuropathol Appl Neurobiol, 28, 390, 10.1046/j.1365-2990.2002.00414.x

Lee, 2009, The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?, Adv Drug Deliv Rev, 61, 1316, 10.1016/j.addr.2009.07.016

Gutzmann, 1998, Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study, J Neural Transm Suppl, 54, 301, 10.1007/978-3-7091-7508-8_30

Wen, 2011, Alternative mitochondrial electron transfer as a novel strategy for neuroprotection, J Biol Chem, 286, 16504, 10.1074/jbc.M110.208447

Galasko, 2012, Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures, Arch Neurol, 69, 836, 10.1001/archneurol.2012.85

Manczak, 2010, Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons, J Alzheimers Dis, 20, 609, 10.3233/JAD-2010-100564

Cardinali, 2010, Clinical aspects of melatonin intervention in Alzheimer's disease progression, Curr Neuropharmacol, 8, 218, 10.2174/157015910792246209

Nicolakakis, 2008, Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist, J Neurosci, 28, 9287, 10.1523/JNEUROSCI.3348-08.2008

Lichtenstein, 2010, Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives, J Alzheimers Dis, 22, 1135, 10.3233/JAD-2010-101332

Choi, 2013, Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease, J Neurochem, 124, 59, 10.1111/jnc.12059

Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann Neurol, 60, 729, 10.1002/ana.21053

Bösel, 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones, J Neurochem, 92, 1386, 10.1111/j.1471-4159.2004.02980.x

Barron, 2006, Reproductive hormones modulate oxidative stress in Alzheimer's disease, Antioxid Redox Signal, 8, 2047, 10.1089/ars.2006.8.2047

Yue, 2007, Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes, Acta Pharmacol Sin, 28, 1129, 10.1111/j.1745-7254.2007.00618.x

Lu, 2006, Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men, Arch Neurol, 63, 177, 10.1001/archneur.63.2.nct50002

Carroll, 2012, The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease, Curr Alzheimer Res, 9, 18, 10.2174/156720512799015109

Jönhagen, 2000, Nerve growth factor treatment in dementia, Alzheimer Dis Assoc Disord, 14, 31, 10.1097/00002093-200000001-00006

Allegri, 2012, Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia, Drugs Today (Barc), 48, 25, 10.1358/dot.2012.48(Suppl.A).1739721

Nikolaev, 2009, APP binds DR6 to trigger axon pruning and neuron death via distinct caspases, Nature, 457, 981, 10.1038/nature07767

Ross, 2007, A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat, Neuropharmacology, 53, 638, 10.1016/j.neuropharm.2007.07.015

Jaffrey, 2001, Protein S-nitrosylation: a physiological signal for neuronal nitric oxide, Nat Cell Biol, 3, 193, 10.1038/35055104

Coban, 2008, Molecular and cellular mechanisms of DNA vaccines, Hum Vaccin, 4, 453, 10.4161/hv.4.6.6200

Bajda, 2011, Multi-target-directed ligands in Alzheimer's disease treatment, Curr Med Chem, 18, 4949, 10.2174/092986711797535245

Yogev-Falach, 2006, A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing, FASEB J, 20, 2177, 10.1096/fj.05-4910fje